Literature DB >> 12359235

TRAIL-induced apoptosis is independent of the mitochondrial apoptosis mediator DAP3.

Thorsten Berger1, Matthias Kretzler.   

Abstract

Tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-induced apoptosis is mediated by its receptors DR4 (TRAIL-R1) and DR5 (TRAIL-R2) and the adapter protein Fas-associated death domain protein (FADD). Recently, an adapter function for death-associated protein 3 (DAP3) between DR4/DR5 and FADD has been proposed. However, DAP3 has been reported to be a ribosomal protein localized to the mitochondrial matrix. To address these discrepancies, the intracellular localization of DAP3 after apoptosis induction in human T-lymphocytes with recombinant TRAIL was analyzed. DAP3, in contrast to cytochrome c, remained intra-mitochondrial during apoptosis. No interaction between FADD and DAP3 after cell fractionation could be detected as long as subcellular compartments remained intact. Only whole cell lysate co-immunoprecipitation revealed an ex vivo interaction between DAP3 and FADD. Therefore, DAP3 and FADD interact only in vitro after disruption of the cellular compartments. TRAIL-induced and DR4-mediated apoptosis in Jurkat cells is independent of DAP3.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12359235     DOI: 10.1016/s0006-291x(02)02310-0

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

Review 1.  Mitochondrial ribosomes in cancer.

Authors:  Hyun-Jung Kim; Priyanka Maiti; Antoni Barrientos
Journal:  Semin Cancer Biol       Date:  2017-04-23       Impact factor: 15.707

Review 2.  Regulating TRAIL receptor-induced cell death at the membrane : a deadly discussion.

Authors:  Sarah Shirley; Alexandre Morizot; Olivier Micheau
Journal:  Recent Pat Anticancer Drug Discov       Date:  2011-09       Impact factor: 4.169

3.  Death-associated protein-3, DAP-3, correlates with preoperative chemotherapy effectiveness and prognosis of gastric cancer patients following perioperative chemotherapy and radical gastrectomy.

Authors:  Y Jia; L Ye; K Ji; L Zhang; R Hargest; J Ji; W G Jiang
Journal:  Br J Cancer       Date:  2013-12-03       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.